Key Points
- LivaNova director Francesco Bianchi sold 1,650 shares at an average price of $79.72, generating $131,538. Following the transaction, he retained 7,934 shares, a 17.22% reduction in his holdings.
- LivaNova’s latest quarterly results exceeded expectations, with earnings per share of $1.26 versus the $1.09 consensus and revenue of $390.59 million, up 10.8% year over year.
- Analyst sentiment remains favorable, with six Buy ratings and five Holds producing a “Moderate Buy” consensus and an average price target of $84.12. Institutional investors own 97.64% of the company’s stock.
LivaNova PLC (NASDAQ:LIVN - Get Free Report) Director Francesco Bianchi sold 1,650 shares of LivaNova stock in a transaction on Monday, August 31st. The stock was sold at an average price of $79.72, for a total transaction of $131,538.00. Following the sale, the director directly owned 7,934 shares in the company, valued at $632,498.48. This trade represents a 17.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
LivaNova Stock Performance
NASDAQ:LIVN opened at $82.40 on Thursday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. The firm has a 50-day moving average of $80.71 and a two-hundred day moving average of $72.72. The stock has a market cap of $4.54 billion, a P/E ratio of 24.38 and a beta of 0.87. LivaNova PLC has a 1-year low of $48.82 and a 1-year high of $85.76.
LivaNova (NASDAQ:LIVN - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The company had revenue of $390.59 million during the quarter, compared to the consensus estimate of $380.50 million. During the same period last year, the firm earned $1.05 earnings per share. The company's revenue was up 10.8% on a year-over-year basis. On average, research analysts expect that LivaNova PLC will post 3.77 earnings per share for the current fiscal year.
Institutional Investors Weigh In On LivaNova
Institutional investors and hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company's stock valued at $1,394,000 after purchasing an additional 1,360 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of LivaNova by 4.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company's stock worth $32,012,000 after buying an additional 36,094 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of LivaNova by 10.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company's stock valued at $6,633,000 after buying an additional 15,405 shares during the period. Intech Investment Management LLC boosted its holdings in shares of LivaNova by 19.6% in the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company's stock valued at $1,724,000 after buying an additional 7,195 shares during the period. Finally, Strs Ohio bought a new stake in shares of LivaNova during the 1st quarter valued at about $130,000. 97.64% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the company. KeyCorp upped their target price on LivaNova from $83.00 to $92.00 and gave the company an "overweight" rating in a research report on Monday, June 22nd. Mizuho lifted their price target on shares of LivaNova from $90.00 to $95.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 15th. Barclays upped their price target on shares of LivaNova from $73.00 to $76.00 and gave the company an "equal weight" rating in a report on Thursday, May 7th. Weiss Ratings upgraded shares of LivaNova from a "hold (c)" rating to a "hold (c+)" rating in a research note on Tuesday, August 18th. Finally, Piper Sandler reissued an "overweight" rating and set a $90.00 price objective (up from $87.00) on shares of LivaNova in a report on Wednesday. Six analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, LivaNova has an average rating of "Moderate Buy" and an average price target of $84.12.
View Our Latest Stock Report on LIVN
About LivaNova
(
Get Free Report)
LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.
The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
